Normative data and clinically significant effect sizes for single-item numerical linear analogue self-assessment (LASA) scales

Health and Quality of Life Outcomes

Jeff A Sloan¹  Jan C Buckner²  Suneetha Pattabasavaiah¹  Daniel Satele¹  Jasvinder A Singh³ 

[1]Department of Health Sciences Research, 200 First Street SW, Rochester 55905, MN, USA

[2]Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA

[3]Department of Orthopaedic Surgery, Mayo Clinic, Rochester, MN, USA

关键词: QOL;    PROs;    Patient-reported outcomes;    Linear analog scale;    Single item;    Validation;    LASA;    Measurement;    Quality of life;   

Others  :  1133910
DOI  :  10.1186/s12955-014-0187-z

 received in 2014-10-09, accepted in 2014-12-08,  发布年份 2014

【 摘 要 】

Background

Single-item assessments have been the most often-used measures in National Cancer Institute (NCI) cancer control clinical trials, but normative data are not available. Our objective was to examine the normative data and clinically significant effect sizes for single-item numerical linear analogue self-assessment (LASA) scale for overall quality of life (QOL).

Methods

We analyzed baseline data from 36 clinical trials and 6 observational studies with various populations, including healthy volunteers, cancer trial patients (patients with advanced incurable cancer or patients receiving treatment with curative intent) and hospice patients as well as their caregivers. The overall QOL LASA was rated 0 (as bad as it can be) to 10 (as good as it can be). We calculated the summary statistics and the proportion of patients reporting a clinically meaningful deficit (CMD) of a score equal to 5 or less on the 0–10 scale.

Results

In total, for the collective sample of 9,295 individuals, the average overall QOL reported was 7.39 (SD = 2.11) with a markedly skewed distribution with roughly 17% reporting a score of 5 or below indicating a clinically significant deficit in overall QOL. Hospice patients report a much worse average score of 5.7 upon entry to hospice; hospice caregivers average 7.4. Cancer patients vary within these two extremes with most patients averaging in the 7’s on the 0–10 scale (range, 0 to 10 p-value < 0.0001). Men and women’s QOL distributions were virtually identical (with average of 7.6 vs. 7.5, p-value = 0.046). Overall QOL was weakly related to performance status with a Spearman correlation coefficient of −0.29 (p-value < 0.0001). Overall QOL was related to tumor response (p-value = 0.0094), i.e. patients with a full or partial response reported a CMD in 11.4% of cases compared to 14.4% among those with stable disease and 18.5% among those with disease progression. Data missingness was high for performance status and tumor response associations.

Conclusions

This study provides the normative data for cancer patients and healthy volunteers for overall QOL using the LASA. These can serve as benchmarks for future studies and inform clinical practice decision-making.

【 授权许可】

   
2014 Singh et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Sloan JA, Zhao X, Novotny PJ, Wampfler J, Garces Y, Clark MM, Yang P: Relationship between deficits in overall quality of life and non-small-cell lung cancer survival. J Clin Oncol 2012, 30:1498-1504.
• [2]Brundage M, Blazeby J, Revicki D, Bass B, de Vet H, Duffy H, Efficace F, King M, Lam CL, Moher D, Scott J, Sloan J, Snyder C, Yount S, Calvert M: Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards. Qual Life Res 2013, 22(6):1161-75.
• [3]Sloan JA, Aaronson N, Cappelleri JC, Fairclough DL, Varricchio C: Assessing the clinical significance of single items relative to summated scores. Mayo Clin Proc 2002, 77:479-487.
• [4]Huschka MM, Mandrekar SJ, Schaefer PL, Jett JR, Sloan JA: A pooled analysis of quality of life measures and adverse events data in north central cancer treatment group lung cancer clinical trials. Cancer 2007, 109:787-795.
• [5]Bernard AL, Prince A, Edsall P: Quality of life issues for fibromyalgia patients. Arthritis Care Res 2000, 13:42-50.
• [6]Stauder MC, Romero Y, Kabat B, Atherton PJ, Geno D, Deschamps C, Jatoi A, Sloan JA, Botros M, Jung KW, Arora AS, Miller RC: Overall survival and self-reported fatigue in patients with esophageal cancer. Support Care Cancer 2013, 21(2):511-519.
• [7]Basch E, Abernethy AP, Mullins CD, Reeve BB, Smith ML, Coons SJ, Sloan J, Wenzel K, Chauhan C, Eppard W, Frank ES, Lipscomb J, Raymond SA, Spencer M, Tunis S: Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol 2012, 30(34):4249-4255.
• [8]Buchanan DR, O'Mara AM, Kelaghan JW, Minasian LM: Quality-of-life assessment in the symptom management trials of the National Cancer Institute-supported Community Clinical Oncology Program. J Clin Oncol 2005, 23:591-598.
• [9]Grunberg SM, Groshen S, Steingass S, Zaretsky S, Meyerowitz B: Comparison of conditional quality of life terminology and visual analogue scale measurements. Qual Life Res 1996, 5:65-72.
• [10]Gudex C, Dolan P, Kind P, Williams A: Health state valuations from the general public using the visual analogue scale. Qual Life Res 1996, 5:521-531.
• [11]Hyland ME, Sodergren SC: Development of a new type of global quality of life scale, and comparison of performance and preference for 12 global scales. Qual Life Res 1996, 5:469-480.
• [12]Sriwatanakul K, Kelvie W, Lasagna L, Calimlim JF, Weis OF, Mehta G: Studies with different types of visual analog scales for measurement of pain. Clin Pharmacol Ther 1983, 34:234-239.
• [13]Wewers ME, Lowe NK: A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health 1990, 13:227-236.
• [14]Berry PH, Dahl JL: The new JCAHO pain standards: implications for pain management nurses. Pain Manag Nurs 2000, 1:3-12.
• [15]Koller A, Miaskowski C, De Geest S, Opitz O, Spichiger E: Results of a randomized controlled pilot study of a self-management intervention for cancer pain. Eur J Oncol Nurs 2013, 17(3):284-91.
• [16]Amtmann D, Cook KF, Jensen MP, Chen WH, Choi S, Revicki D, Cella D, Rothrock N, Keefe F, Callahan L, Lai JS: Development of a PROMIS item bank to measure pain interference. Pain 2010, 150:173-182.
• [17]Cleeland CS, Sloan JA, Cella D, Chen C, Dueck AC, Janjan NA, Liepa AM, Mallick R, O'Mara A, Pearson JD, Torigoe Y, Wang XS, Williams LA, Woodruff JF: CPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force: Recommendations for including multiple symptoms as endpoints in cancer clinical trials: a report from the ASCPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force. Cancer 2013, 119:411-420.
• [18]Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, Engstrom MC: Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 2000, 89:1634-1646.
• [19]Wanous JP: Single-item reliability: a replication and extension. Organ Res Meth 2001, 4:361-375.
• [20]Ganz PA, Lee JJ, Siau J: Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer 1991, 67:3131-3135.
• [21]Gotay CC, Kawamoto CT, Bottomley A, Efficace F: The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 2008, 26:1355-1363.
• [22]Efficace F, Bottomley A, Smit EF, Lianes P, Legrand C, Debruyne C, Schramel F, Smit HJ, Gaafar R, Biesma B, Manegold C, Coens C, Giaccone G, Van Meerbeeck J: EORTC Lung Cancer Group and Quality of Life Unit: Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol 2006, 17:1698-1704.
• [23]Norman GR, Sloan JA, Wyrwich KW: The truly remarkable universality of half a standard deviation: confirmation through another look. Expet Rev Pharmacoecon Outcomes Res 2004, 4:581-585.
• [24]Butt Z, Wagner LI, Beaumont JL, Paice JA, Peterman AH, Shevrin D, Von Roenn JH, Carro G, Straus JL, Muir JC, Cella D: Use of a single-item screening tool to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory cancer practice. J Pain Symptom Manage 2008, 35:20-30.
• [25]Bretscher M, Rummans T, Sloan J, Kaur J, Bartlett A, Borkenhagen L, Loprinzi C: Quality of life in hospice patients. A pilot study. Psychosomatics 1999, 40:309-313.
• [26]Velanovich V, Wollner I: Quality of life and performance status in patients with pancreatic and periampullary tumors. Int J Clin Oncol 2011, 16:401-407.
• [27]Sloan JA, Grothery A, Green E, Zhao X, Campbell ME, Szydio DW, Sargent DJ, Goldeberg RM: Tumor response is not related to quality of life in patients with metastatic colorectal cancer (abstract). J Clin Oncol 2008, 26:4017.
• [28]Snyder CF, Watson ME, Jackson JD, Cella D, Halyard MY: Patient-reported outcome instrument selection: designing a measurement strategy. Value Health 2007, 10(Suppl 2):S76-S85.
• [29]Velikova G, Awad N, Coles-Gale R, Wright EP, Brown JM, Selby PJ: The clinical value of quality of life assessment in oncology practice-a qualitative study of patient and physician views. Psychooncology 2008, 17:690-698.
• [30]Asadi-Lari M, Tamburini M, Gray D: Patients' needs, satisfaction, and health related quality of life: towards a comprehensive model. Health Qual Life Outcomes 2004, 2:32. BioMed Central Full Text
• [31]Sloan JA, Loprinzi CL, Kuross SA, Miser AW, O'Fallon JR, Mahoney MR, Heid IM, Bretscher ME, Vaught NL: Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol 1998, 16:3662-3673.
• [32]Fayers P, Machin D: Single gobal questions versus multi-item scales. In Quality of life: The assessment, analysis and interpretation of patient-reported outcomes. 2nd edition. John Wiley & Sons, Somerset, NJ; 2013. Section 2.5
• [33]Zimmerman M, Ruggero CJ, Chelminski I, Young D, Posternak MA, Friedman M, Boerescu D, Attiullah N: Developing brief scales for use in clinical practice: the reliability and validity of single-item self-report measures of depression symptom severity, psychosocial impairment due to depression, and quality of life. J Clin Psychiatry 2006, 67:1536-1541.
• [34]Yohannes AM, Dodd M, Morris J, Webb K: Reliability and validity of a single item measure of quality of life scale for adult patients with cystic fibrosis. Health Qual Life Outcomes 2011, 9:105. BioMed Central Full Text
• [35]Krause NM, Jay GM: What do global self-rated health items measure? Med Care 1994, 32:930-942.
• [36]Hubbard JM, Grothey AF, McWilliams RR, Buckner JC, Sloan JA: Physician perspective on incorporation of oncology patient quality-of-life, fatigue, and pain assessment into clinical practice. J Oncol Pract 2014, 10:248-253.
• [37]Bowling A: Just one question: If one question works, why ask several? J Epidemiol Community Health 2005, 59:342-345.
• [38]Somerfield MR: Wherefore global quality-of-life assessment? J Clin Oncol 1999, 17:738-740.
• [39]Laine C, Davidoff F: Patient-centered medicine. A professional evolution. JAMA 1996, 275:152-156.
• [40]Zwarenstein M, Goldman J, Reeves S: Interprofessional collaboration: effects of practice-based interventions on professional practice and healthcare outcomes.Cochrane Database Syst Rev 2009(3):CD000072. doi:10.1002/14651858.CD000072.pub2.
• [41]Blazeby JM, Wilson L, Metcalfe C, Nicklin J, English R, Donovan JL: Analysis of clinical decision-making in multi-disciplinary cancer teams. Ann Oncol 2006, 17:457-460.